TERAFLU EKSTRATAB

Active material: Xlorfenamin, Paracetamol, Phenylephrine
When ATH: N02BE51
CCF: The drug for the symptomatic treatment of acute respiratory diseases
When CSF: 03.02.01.03
Manufacturer: NOVARTIS CONSUMER HEALTH S.A. (Switzerland)

dosage form, composition and packaging

◊ Pills, Film-coated light yellow, oblong, with beveled edges; of presentations – light yellow.

Excipients: colloidal silicon dioxide, Lac (on the basis of quinoline yellow dye), lactose, magnesium stearate, giproloza, Croscarmellose sodium, corn starch.

The composition of the coating film: Lac (on the basis of quinoline yellow dye), quinoline yellow dye, Titanium dioxide, Titanium dioxide, metilparagidroksiʙenzoat, povidone, colloidal silicon dioxide, macrogol 400, methyl cellulose.

10 PC. – blisters (1) – packs cardboard.
10 PC. – blisters (2) – packs cardboard.

Pharmacokinetics

Terflu Jekstratab-combined product, with antipyretic, backflow, analgesic and anti-allergic effect.
Contains active ingredients, to help alleviate the symptoms of colds and flu (fever, headache, joint pain, stuffy nose, swelling of the nasal mucosa). Paracetamol has analgesic and antipyretic effect; feniramina maleate and phenylephrine HCL inhibit secretion and reduces swelling of mucous membrane. Farmakodinamika: Paracetamol is rapidly and completely absorbed from the gastrointestinal tract. Its maximum concentration in plasma achieved after 30-60 minutes. In the application of therapeutic doses of half-time is 1-4 o'clock. Metabolised mainly in the liver, forming bile acids with conjugates. But, Depending on the concentration of plasma, paracetamol can partially be subjected to deacetilirovanija or hydroxylation reactions to nitrogen. Through 24 o'clock 90-100% from the input of the dose excreted news in the form of glukuronidov (60%), sulphates (35%) or the cysteine conjugates (3%).
The maximum concentration of Feniramina maleate in plasma is after 1-2.5 o'clock; half-term is 16-19 hours. 70-83% from the lane oral dose excreted in the urine in unchanged form or in the form of metabolites.
Phenylephrine has very limited biodostupnostthew due to poor absorption from the gastrointestinal tract and rapid metabolism in the gut and liver, implemented by monoaminoxydasa.

Indications

Symptomatic therapy of infectious and inflammatory diseases (acute respiratory viral infection, flu)
– heat
– headache
– rhinorrhea (cold)
– nasal congestion
– sneezing
– muscle aches. Dosing and Administration: Inside, by 1 per tablet 6 hours. Swallow the Tablet whole, without chewing, drinking water. The maximum daily dose for adults – 6 pill per day, for children over 12 years – 4 tablets per day.

Side effects

Skin rash, itch, hives, angioedema
– nausea, epigastric pain, dry mouth
– drowsiness
– midriaz
– Parez akkomodacii
– urinary retention
– increased intraocular pressure
– rare anemia, thrombocytopenia, agranulocytosis
– hypererethism, dizziness
– high blood pressure
– with long-term use in high doses, hepatotoxic action, gemoliticheskaya anemia, aplasticheskaya anemia, metgemoglobinemiâ, pancytopenia
– nephrotoxicity (počečnaâ how, glycosuria, interstitial nephritis, papillary necrosis).

Contraindications

Hypersensitivity to the preparation components
– pregnancy, lactation
– Children up to age 12 years.

Drug interactions

Symptoms – nausea, vomiting, epigastric pain; gepatotoksicescoe and nefrotoksicescoe actions, in severe cases develop liver failure, encephalopathy and coma.
Treatment – gastric lavage, activated charcoal in the first 6 no, introduction of donators SH-groups and precursors of glutathione synthesis – through methionine 8-9 hours after the overdose and N-acetylcysteine
through 12 no.

Cautions

The risk of hepatotoxicity of paracetamol is increased with concomitant administration of barbiturates, difenina, karʙamazepina, rifampicin, AZT and other inducers of microsomal liver enzymes.
Do effects of monoamine oxidase inhibitors, sedative drugs, ethanol. It is recommended to refrain from taking the drug when taken monoamine oxidase inhibitors. Ethanol increases the sedative antihistamine medicines. Antidepressants, phenothiazine derivatives, anti-parkinsonian N04 and antipsychotic drugs increase the risk of developing urinary retention, dry mouth, constipation. Glukokorticosteroida increase the risk of glaucoma.
Paracetamol reduces the effectiveness of urikozuricheskih medicines.
Chlorphenamine simultaneously with monoamine oxidase inhibitors, furazolidone can lead to a hypertensive crisis, excitation, giperpireksii. Tricyclic antidepressants increase the effect of phenylephrine adrenomimeticescoe, co-administration of halothane increases the risk of ventricular arrhythmias. Reduces hypotensive effect of guanethidine, which, in turn, It increases the activity of alpha-adrenostimuliruyuschee phenylephrine.

Overdose

In order to avoid toxic to liver dose should not be combined with the use of alcoholic beverages.

Especially the influence of the drug on the ability to drive vehicles and particularly dangerous machinery

During treatment is not recommended to drive a car or other mechanisms, requiring concentration and high speed psychomotor reactions.

Carefully

Arterial hypertension, diabetes, zakrыtougolynaya glaucoma, severe liver disease or kidney disease, prostatic hyperplasia, blood disease, deficiency of glucose-6-fosfatdegidrogenazы, thyrotoxicosis, bronchial asthma, COPD (emphysema, chronic bronchitis).

Product form

# 10 pills in blister PVC and aluminium foil. By 1 or 2 blisters, together with instructions for use in paper cartons.

Storage conditions

Shelf life

Conditions of supply of pharmacies